VerifyNow® P2Y12 Test
Thienopyridines such as Plavix® (clopidogrel) and Effient® (prasugrel) block the P2Y12 ADP binding site on the platelet. The VerifyNow P2Y12 Test uses an ADP agonist to induce platelet activation and ascertain the level of platelet reactivity impaired by these medications. It also incorporates a second channel containing thrombin receptor agonists to approximate baseline reactivity so that there is no need to discontinue antiplatelet medication. Studies show that up to 30% of patients taking Plavix have low levels of platelet inhibition (reactivity)1,2 and do not receive the expected antiplatelet effect which may increase the risk of ischemic events or unnecessarily delayed from surgery. The quantitative test is a simple measurement to help assess the patient’s level of response to their therapy.
VerifyNow P2Y12 Test also Measures Response to Prasugrel
With the recent FDA approval of the new P2Y12 inhibitor, prasugrel (Effient®), Accumetrics, Inc. announces that its VerifyNow P2Y12 Test is not only able to assess response to Plavix, but also the newly approved Effient. In obtaining a result from the VerifyNow System, physicians are provided objective information to determine the response of an individual patient to their antiplatelet therapy, regardless of the P2Y12 inhibitor that is prescribed. Click here for more information. 
Additional Documentation
Instructions for Use (PDF)
VerifyNow System (PDF)
Waiting for Clopidogrel (PDF)
Interventional Cardiology Brochure (PDF)
INTENDED USE
The VerifyNow P2Y12 Assay is a whole blood assay used in the laboratory or point of care setting to measure the level of platelet P2Y12 receptor blockade.
References :
- Malinin, A. et al. Monitoring Platelet Inhibition after Clopidogrel with the VerifyNow P2Y12 Analyzer: The Verify Thrombosis Risk Assessment (Veritas Study). Thromb Res 2007;119(3):277-284.
- Serebruany, VL. et al. Variability in Platelet Responsiveness to Clopidogrel among 544 Individuals. J Am Coll Cardiol 2005;45:246-51.
